tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kazia Therapeutics price target raised to $20 from $15 at Maxim

Maxim raised the firm’s price target on Kazia Therapeutics (KZIA) to $20 from $15 and keeps a Buy rating on the shares. The company has made significant progress in developing paxalisib for triple-negative breast cancer and has read out consistently positive data across both TNBC and ER+/HER2-breast cancer, and while it’s early stage, the data thus far appears promising, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1